[Treatment guidelines for ankylosing spondylitis and its effect on Mexican rheumatology].
We describe the guidelines for the current treatment of ankylosing spondylitis with an emphasis on the role and outlook of the Mexican rheumatologic community. The topics we analyze include: epidemiological as well as professional, financial, health status, and quality of life aspects. We propose to acknowledge that axial spondyloarthritis is the earliest form of ankylosing spondylitis. Finally we carry out a review of the literature supporting current therapeutic recommendations. Regarding the latter, we approached the ASAS/EULAR recommendations for the treatment of ankylosing spondylitis and their level of agreement with Mexican and other countries' rheumatologists. Finally, we analyzed the recommendations to start tumor necrosis alpha blockers among patients with ankylosing spondylitis.
Burgos-Vargas
Rubén
R
Servicio de Reumatología, Hospital General de México, Dr. Balmis 148, Col. Doctores, Del. Cuauhtémoc, 06720 México D.F., México. burgosv@prodigy.net.mx
Abud-Mendoza
Carlos
C
Díaz-Jouanen
Efraín
E
Garza-Elizondo
Mario A
MA
Medrano-Ramírez
Gabriel
G
Orozco-Alcalá
Javier
J
Pacheco-Tena
César
C
Pineda-Villaseñor
Carlos
C
Carlos-Pozos
Juan
J
Ramos-Niembro
Francisco
F
Robles-San Román
Manuel
M
Santana-Sahagún
Ernesto
E
D006801:Humans; D008800:Mexico; D017410:Practice Guidelines as Topic; D012219:Rheumatology; D013167:Spondylitis, Ankylosing / Q000628:therapy*